Flu Vaccine Guidelines

Introduction; Flucelvax Quadrivalent (ccIIV4) Phase III Randomized Controlled Trial—Immunogenicity and Safety in Children 6 through 47 months; Work group considerations and proposed recommendations for the 2021-22 Influenza Season; Updates to Influenza VFC Resolution

This video can also be viewed at